The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics
Open accessAbstract
BACKGROUND: The epidermal growth factor receptor (EGFR) plays a critical role in the control of cellular proliferation, differentiation, and survival. Abnormalities in EGF-EGFR signaling, such as mutations that render the EGFR hyperactive or cause overexpression of the wild-type receptor, have been found in a broad range of cancers, including carcinomas of the lung, breast, and colon. EGFR inhibitors such as gefitinib have proven successful in the treatment of certain cancers, particularly non-small cell lung cancers (NSCLCs) harboring activating mutations within the EGFR gene, but the molecular mechanisms leading to tumor regression remain unknown. Therefore, we wished to delineate these mechanisms. METHODS AND FINDINGS: We performed biochemical and genetic studies to investigate the mechanisms by which inhibitors of EGFR tyrosine kinase activity, such as gefitinib, inhibit the growth of human NSCLCs. We found that gefitinib triggered intrinsic (also called "mitochondrial") apoptosis signaling, involving the activation of BAX and mitochondrial release of cytochrome c, ultimately unleashing the caspase cascade. Gefitinib caused a rapid increase in the level of the proapoptotic BH3-only protein BIM (also called BCL2-like 11) through both transcriptional and post-translational mechanisms. Experiments with pharmacological inhibitors indicated that blockade of MEK-ERK1/2 (mitogen-activated protein kinase kinase-extracellular signal-regulated protein kinase 1/2) signaling, but not blockade of PI3K (phosphatidylinositol 3-kinase), JNK (c-Jun N-terminal kinase or mitogen-activated protein kinase 8), or AKT (protein kinase B), was critical for BIM activation. Using RNA interference, we demonstrated that BIM is essential for gefitinib-induced killing of NSCLC cells. Moreover, we found that gefitinib-induced apoptosis is enhanced by addition of the BH3 mimetic ABT-737. CONCLUSIONS: Inhibitors of the EGFR tyrosine kinase have proven useful in the therapy of certain cancers, in particular NSCLCs possessing activating mutations in the EGFR kinase domain, but the mechanisms of tumor cell killing are still unclear. In this paper, we demonstrate that activation of the proapoptotic BH3-only protein BIM is essential for tumor cell killing and that shutdown of the EGFR-MEK-ERK signaling cascade is critical for BIM activation. Moreover, we demonstrate that addition of a BH3 mimetic significantly enhances killing of NSCLC cells by the EGFR tyrosine kinase inhibitor gefitinib. It appears likely that this approach represents a paradigm shared by many, and perhaps all, oncogenic tyrosine kinases and suggests a powerful new strategy for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · cited 1×
“The EGFR tyrosine kinase inhibitors gefitinib (Iressa, AstraZeneca) and erlotinib (Tarceva, Genentech) as well as the monoclonal antibody cetuximab (Erbitux, Merck), which blocks ligand binding, cause substantial regression of a small proportion of non-small cell lung cancers (NSCLCs), particularly those with EGFRmuta…”
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
The Pathophysiology of Mitochondrial Cell Death
Green, D. R., & Kroemer, G. (2004) · Science · doi:10.1126/science.1099320 · Cited by 3,418
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
Zha, J., Harada, H., Yang, E., Jockel, J., & Korsmeyer, S. J. (1996) · Cell · doi:10.1016/s0092-8674(00)81382-3 · Cited by 2,595
The molecular biology of chronic myeloid leukemia
Deininger, M. W. N., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.10.3343 · Cited by 1,667
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,606
Bouillet, P., Metcalf, D., Huang, D. C. S., Tarlinton, D. M., Kay, T. W. H., Köntgen, F., Adams, J. M., & Strasser, A. (1999) · Science · doi:10.1126/science.286.5445.1735 · Cited by 1,504
Self-citationp53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa
Villunger, A., Michalak, E. M., Coultas, L., Müllauer, F., Böck, G., Ausserlechner, M. J., Adams, J. M., & Strasser, A. (2003) · Science · doi:10.1126/science.1090072 · Cited by 1,327
Self-citationStatus of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J., & Baselga, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,255
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
Deininger, M., Buchdunger, E., & Druker, B. J. (2005) · Blood · doi:10.1182/blood-2004-08-3097 · Cited by 1,253
Bim: a novel member of the Bcl-2 family that promotes apoptosis
O'Connor, L. (1998) · The EMBO Journal · doi:10.1093/emboj/17.2.384 · Cited by 1,166
BH3-Only Proteins—Essential Initiators of Apoptotic Cell Death
Huang, D. C. S., & Strasser, A. (2000) · Cell · doi:10.1016/s0092-8674(00)00187-2 · Cited by 1,043
Self-citationPuma is an essential mediator of p53-dependent and -independent apoptotic pathways
Jeffers, J. R., Parganas, E., Lee, Y., Yang, C., Wang, J., Brennan, J., MacLean, K. H., Han, J., Chittenden, T., Ihle, J. N., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00244-7 · Cited by 879
Bcl‐2 and Fas/APO‐1 regulate distinct pathways to lymphocyte apoptosis.
Strasser, A., Harris, A. W., Huang, D. C., Krammer, P. H., & Cory, S. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00304.x · Cited by 784
Self-citationPuthalakath, H., & Strasser, A. (2002) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400998 · Cited by 722
Self-citationLey, R., Balmanno, K., Hadfield, K., Weston, C., & Cook, S. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301010200 · Cited by 608
Politi, K., Zakowski, M. F., Fan, P.-D., Schonfeld, E. A., Pao, W., & Varmus, H. E. (2006) · Genes & Development · doi:10.1101/gad.1417406 · Cited by 478 · cited 1×
“]). Moreover, enforced expression of mutant EGFR in transgenic mice promoted development of lung carcinomas [”
Luciano, F., Jacquel, A., Colosetti, P., Herrant, M., Cagnol, S., Pages, G., & Auberger, P. (2003) · Oncogene · doi:10.1038/sj.onc.1206792 · Cited by 477
Ji, H., Li, D., Chen, L., Shimamura, T., Kobayashi, S., McNamara, K., Mahmood, U., Mitchell, A., Sun, Y., Al-Hashem, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.022 · Cited by 462
FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal
You, H., Pellegrini, M., Tsuchihara, K., Yamamoto, K., Hacker, G., Erlacher, M., Villunger, A., & Mak, T. W. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060353 · Cited by 412
BARNETT, S. F., DEFEO-JONES, D., FU, S., HANCOCK, P. J., HASKELL, K. M., JONES, R. E., KAHANA, J. A., KRAL, A. M., LEANDER, K., LEE, L. L., et al. (2005) · Biochemical Journal · doi:10.1042/bj20041140 · Cited by 396
Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255
Tracy, S., Mukohara, T., Hansen, M., Meyerson, M., Johnson, B. E., & Jänne, P. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1905 · Cited by 374
Janmaat, M. L., Kruyt, F. A. E., Rodríguez, J. A., & Giaccone, G. (2003) · PubMed · Cited by 356
Kuroda, J., Puthalakath, H., Cragg, M. S., Kelly, P. N., Bouillet, P., Huang, D. C. S., Kimura, S., Ottmann, O. G., Druker, B. J., Villunger, A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606176103 · Cited by 336
Self-citationMukohara, T., Engelman, J. A., Hanna, N. H., Yeap, B. Y., Kobayashi, S., Lindeman, N., Halmos, B., Pearlberg, J., Tsuchihashi, Z., Cantley, L. C., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji238 · Cited by 318
Regulatory phosphorylation of Bim: sorting out the ERK from the JNK
Ley, R., Ewings, K. E., Hadfield, K., & Cook, S. J. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401688 · Cited by 313
Essafi, A., Fernández de Mattos, S., Hassen, Y. A. M., Soeiro, I., Mufti, G. J., Thomas, N. S. B., Medema, R. H., & Lam, E. W.-F. (2005) · Oncogene · doi:10.1038/sj.onc.1208421 · Cited by 293
Kobayashi, S., Ji, H., Yuza, Y., Meyerson, M., Wong, K.-K., Tenen, D. G., & Halmos, B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1346 · Cited by 272
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336
Hoover, R. R., Mahon, F.-X., Melo, J. V., & Daley, G. Q. (2002) · Blood · doi:10.1182/blood.v100.3.1068 · Cited by 241
Akiyama, T. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg635 · Cited by 241
Bouillet, P., Zhang, L. C., Huang, D. C. S., Webb, G. C., Bottema, C. D. K., Shore, P., Eyre, H. J., Sutherland, G. R., & Adams, J. M. (2001) · Mammalian Genome · doi:10.1007/s003350010242 · Cited by 139
Self-citationNaik, E., Michalak, E. M., Villunger, A., Adams, J. M., & Strasser, A. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200608070 · Cited by 135
Self-citationHelfrich, B. A., Raben, D., Varella‐Garcia, M., Gustafson, D., Chan, D. C. F., Bemis, L., Coldren, C. D., Barón, A. E., Zeng, C., Franklin, W. A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0760 · Cited by 129
Komatsu, N., Watanabe, T., Uchida, M., Mori, M., Kirito, K., Kikuchi, S., Liu, Q., Tauchi, T., Miyazawa, K., Endo, H., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211562200 · Cited by 119
Dewson, G., Snowden, R. T., Almond, J. B., Dyer, M. J. S., & Cohen, G. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206326 · Cited by 100
Complement mediated cell death is associated with DNA fragmentation
Cragg, M. S., Howatt, W. J., Bloodworth, L., Anderson, V. A., Morgan, B. P., & Glennie, M. J. (2000) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400627 · Cited by 55
Self-citationPolycystic kidney disease prevented by transgenic RNA interference
Bouillet, P., Robati, M., Bath, M. L., & Strasser, A. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401603 · Cited by 30
Self-citation
Cited by
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
Self-citationTargeting mitochondria for cancer therapy
Fulda, S., Galluzzi, L., & Kroemer, G. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3137 · Cited by 1,629
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083
Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.003 · Cited by 801
Metadata
- Authors
- Cragg, M. S., Kuroda, J., Puthalakath, H., Huang, D. C. S., & Strasser, A.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-10-30
- Volume
- 4
- Issue
- 10
- Pages
- e316
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2152636515
- Cited by
- 343
- References
- 40
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.